Generate Biomedicines, Inc. Statistics
Want to see GENB full AI Analyst Report?
Generate Biomedicines, Inc. (GENB) Stock Statistics & Valuation Metrics
Total Valuation
Generate Biomedicines, Inc. has a market cap or net worth of $1.68B. The enterprise value is $1.77B.
- Market Cap
- $1.68B
- Enterprise Value
- $1.77B
Share Statistics
Generate Biomedicines, Inc. has 128,352,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 128,352,430
- Owned by Insiders
- 52.36%
- Owned by Institutions
- 14.71%
Financial Efficiency
Generate Biomedicines, Inc.’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is -89.38%.
- Return on Equity (ROE)
- 0.33
- Return on Assets (ROA)
- -0.62
- Return on Invested Capital (ROIC)
- -89.38%
- Return on Capital Employed (ROCE)
- -0.95
- Revenue Per Employee
- 102.22K
- Profits Per Employee
- -651.13K
- Employee Count
- 312
- Asset Turnover
- 0.10
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Generate Biomedicines, Inc. is -8.39. Generate Biomedicines, Inc.’s PEG ratio is -0.08.
- PE Ratio
- -8.39
- PS Ratio
- 76.90
- PB Ratio
- 3.99
- Price to FCF
- -9.48
- Price to Operating Cash Flow
- -9.72
- PEG Ratio
- -0.08
Income Statement
In the last 12 months, Generate Biomedicines, Inc. had revenue of 31.89M and earned -203.15M in profits. Earnings per share was -4.98.
- Revenue
- 31.89M
- Gross Profit
- 31.89M
- Operating Income
- -235.06M
- Pretax Income
- -222.80M
- Net Income
- -203.15M
- EBITDA
- -208.49M
- Earnings Per Share (EPS)
- -4.98
Cash Flow
In the last 12 months, operating cash flow was -138.33M and capital expenditures -4.71M, giving a free cash flow of -143.05M billion.
- Operating Cash Flow
- -138.33M
- Free Cash Flow
- -143.05M
- Free Cash Flow per Share
- -1.50
Dividends & Yields
Generate Biomedicines, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -10.54%
- Earnings Yield
- -9.95%
Stock Price Statistics
- Beta
- 0.86
- 52-Week Price Change
- 3.24%
- 50-Day Moving Average
- 14.63
- 200-Day Moving Average
- 14.08
- Relative Strength Index (RSI)
- 45.97
- Average Volume (3m)
- 1.22M
Important Dates
Generate Biomedicines, Inc. upcoming earnings date is ―, Before Open (Confirmed).
- Last Earnings Date
- Aug 06, 2026
- Next Earnings Date
- ―
- Ex-Dividend Date
- ―
Financial Position
Generate Biomedicines, Inc. as a current ratio of 2.85, with Debt / Equity ratio of -11.12%
- Current Ratio
- 2.85
- Quick Ratio
- 2.85
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.25
- Interest Coverage Ratio
- -206.92
Taxes
In the past 12 months, Generate Biomedicines, Inc. has paid 163.00K in taxes.
- Income Tax
- 163.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Generate Biomedicines, Inc. EV to EBITDA ratio is -9.84, with an EV/FCF ratio of -9.11.
- EV to Sales
- 73.88
- EV to EBITDA
- -9.84
- EV to Free Cash Flow
- -9.11
- EV to Operating Cash Flow
- -9.35
Balance Sheet
Generate Biomedicines, Inc. has $457.42M in cash and marketable securities with $62.63M in debt, giving a net cash position of $394.79M billion.
- Cash & Marketable Securities
- $457.42M
- Total Debt
- $62.63M
- Net Cash
- $394.79M
- Net Cash Per Share
- $3.08
- Tangible Book Value Per Share
- $3.56
Margins
Gross margin is 86.17%, with operating margin of -827.60%, and net profit margin of -765.29%.
- Gross Margin
- 86.17%
- Operating Margin
- -827.60%
- Pretax Margin
- -784.12%
- Net Profit Margin
- -765.29%
- EBITDA Margin
- -750.93%
- EBIT Margin
- -792.42%
Analyst Forecast
The average price target for Generate Biomedicines, Inc. is $26.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $26.00
- Price Target Upside
- 99.08% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 7
- AI Score
- 45
